INCREASED SYSTEMIC BIOAVAILABILITY OF ALBENDAZOL WHEN ADMINISTERED WITH SURFACTANTS IN RATS

被引:14
作者
DELESTAL, JL [1 ]
ALVAREZ, AI [1 ]
VILLAVERDE, C [1 ]
JUSTEL, A [1 ]
PRIETO, JG [1 ]
机构
[1] UNIV LEON,DEPT PHYSIOL PHARMACOL & TOXICOL,E-24071 LEON,SPAIN
关键词
ALBENDAZOL; BIOAVAILABILITY; SURFACTANT; RAT;
D O I
10.1016/0378-5173(94)90063-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This work describes the determination of the plasma concentrations of albendazol sulfoxide (ABZ.SO) after administration of single oral doses of albendazol (ABZ) using surfactants as vehicles (Tween 80 and sodium taurocholate). The pharmacokinetic parameters AUC, C-max and t(max) were affected by the use of surfactants. The results showed higher plasma levels of ABZ.SO and the ratio, AUC/initial dose, was 60-100-times greater in the presence of surfactants.
引用
收藏
页码:257 / 260
页数:4
相关论文
共 8 条
[1]   SPECIES-DIFFERENCES IN THE GENERATION OF THE CHIRAL SULFOXIDE METABOLITE OF ALBENDAZOLE IN SHEEP AND RATS [J].
DELATOUR, P ;
BENOIT, E ;
CAUDE, M ;
TAMBUTE, A .
CHIRALITY, 1990, 2 (03) :156-160
[2]   EFFECT OF SURFACTANTS ON ALBENDAZOLE ABSORPTION [J].
DELESTAL, JL ;
ALVAREZ, AI ;
VILLAVERDE, C ;
CORONEL, P ;
FABRA, S ;
PRIETO, JG .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (10-12) :1161-1164
[3]   COMPARATIVE EFFECTS OF ANIONIC, NATURAL BILE-ACID SURFACTANTS AND MIXED MICELLES ON THE INTESTINAL-ABSORPTION OF THE ANTHELMINTIC ALBENDAZOLE [J].
DELESTAL, JL ;
ALVAREZ, AI ;
VILLAVERDE, C ;
PRIETO, JG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 91 (2-3) :105-109
[4]  
GRANDE LAG, 1987, ENF INFEC MICROBIOL, V5, P627
[5]   PHARMACOKINETICS OF ALBENDAZOLE IN MAN [J].
MARRINER, SE ;
MORRIS, DL ;
DICKSON, B ;
BOGAN, JA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :705-708
[6]   EXPERIMENTAL AND THEORETICAL-STUDIES OF ALBENDAZOLE, OXIBENDAZOLE, AND TIOXIDAZOLE [J].
MCCRACKEN, RO ;
LIPKOWITZ, KB .
JOURNAL OF PARASITOLOGY, 1990, 76 (02) :180-185
[7]  
POELMA FGJ, 1990, ACTA PHARM TECHNOL, V36, P43
[8]  
SOUHAILIELAMRI H, 1988, TOXICOL APPL PHARM, V92, P141, DOI 10.1016/0041-008X(88)90236-0